Camurati-Engelmann Disease.

Area of Science:

• Genetics
• Orthopedics
• Rare Diseases

Background:

• Camurati-Engelmann disease (progressive diaphyseal dysplasia) is a rare autosomal dominant sclerosing bone dysplasia.
• Primarily affects the skull and diaphyses of long bones.
• Clinical manifestations include bone pain, fatigue, proximal lower limb muscle weakness, and gait disturbances.

Purpose of the Study:

• To review the clinical and radiological characteristics of Camurati-Engelmann disease.
• To discuss the molecular genetics underlying the condition.
• To explore potential therapeutic targets and current treatment limitations.

Main Methods:

• Literature review of clinical, radiological, and genetic studies.
• Analysis of the role of TGFβ-1 gene mutations.
• Discussion of preclinical and clinical findings regarding treatment.

Main Results:

• Mutations in the TGFβ-1 gene disrupt TGFβ1 binding, leading to increased pathway signaling and accelerated bone turnover.
• Preclinical studies indicate that targeting the type I receptor can ameliorate high bone turnover.
• Current patient treatments, mainly corticosteroids, offer symptomatic relief for pain and muscle weakness.

Conclusions:

• Camurati-Engelmann disease is characterized by specific skeletal and clinical features linked to TGFβ-1 gene mutations.
• Understanding the molecular mechanisms provides a basis for developing targeted therapies.
• Further research is needed to optimize treatment strategies beyond corticosteroids for this rare bone dysplasia.